Tertiary Phosphorus Removal: An Effective Treatment Strategy for Reuse Applications

2007 ◽  
Vol 2007 (10) ◽  
pp. 7530-7531
Author(s):  
Mark Steichen ◽  
Derek Cambridge ◽  
Ed Kobylinski ◽  
Andrew Hansen ◽  
Mary Fralish
Keyword(s):  
Effective Treatment ◽  
Treatment Strategy ◽  
Phosphorus Removal

scholarly journals The Role of Pharmacogenetics in the Treatment of Diabetes Mellitus / ULOGA FARMAKOGENETIKE U LEČNJU DIJABETES MELITUSA

2014 ◽  
Vol 33 (1) ◽  
pp. 58-70 ◽  
Author(s):  
Elizabeta Topić
Keyword(s):  
Diabetes Mellitus ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Screening Program ◽  
Economic Consequences ◽  
Dipeptidyl Peptidase 4 ◽  
Glucosidase Inhibitors ◽  
Baseline Information ◽  
Approved Drugs ◽  
Therapeutic Decision Making

Summary Diabetes mellitus is a heterogeneous group of disorders in which particular disease phenotypes can be characterized by a specific etiology and/or pathogenesis of the disease, but in many cases its classification is greatly impeded due to significant phenotype overlapping. Diabetes is a wordwide epidemic with significant health and economic consequences. The frequency of type 2 diabetes (T2D) is much higher than type 1 diabetes (T1D). In adults, around 285 million people suffer from T2DM with a projected rise to 438 million in the next 20 years. A variety of pharmacological treatments exist for patients with T2D, in addition to dietary and physical activity. Pharmacologically, diabetes is treated with nine major classes of approved drugs, including insulin and its analogues, sulfonylureas, biguanides, thiazolidinediones (TZDs), meglitinides, a-glucosidase inhibitors, amylin analogues, incretin hormone mimetics, and dipeptidyl peptidase 4 (DPP4) inhibitors. Treatment strategy for T2D is based mostly on oral hypoglycemic drug (OHD) efficacy assessed usually by HbA1c and/or fasting plasma glucose. The patients are often treated with more than one OHD in combination with the purpose to receive more effective treatment. Characterization of drug response is expected to substantially increase the ability to provide patients with the most effective treatment strategy. If pharmacogenetic testing for diabetes drugs could be used to predict treatment outcome, appropriate measures could be taken to treat T2D more efficiently. To date, major pharmacogenetic studies have focused on response to sulfonylureas, biguanides, and TZDs, the most used OHD. A comprehensive review of the pharmacogenetic studies of specific OHD is presented in this article. Understanding the pharmacogenetics of these drugs will provide critical baseline information for the development and implementation of a genetic screening program into therapeutic decision making, enabling a personalized medicine approach for T2D patients.

scholarly journals Effective treatment of different types of polycystic ovary syndrome in adolescent girls

2022 ◽  
pp. 56-60
Author(s):  
E. V. Uvarova ◽  
E. P. Khashchenko ◽  
S. O. Kyurdzidi
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Effective Treatment ◽  
Adolescent Girls ◽  
Treatment Strategy ◽  
Polycystic Ovary ◽  
Young Female ◽  
Diagnosis And Treatment ◽  
Medical Community ◽  
Ovary Syndrome ◽  
Female Patients

This review is addressing an urgent problem of diagnosis and treatment strategy of polycystic ovary syndrome in adolescent girls. We analysed data from modern literary publications on the epidemiology and classification of the disease, as well as the adaptation of general principles for the management of young female patients tailored to their age peculiarities. The effective treatment strategies for adolescent girls with PCOS depending on its type are presented. Today there are several contradictions associated with both the diagnosis and treatment of the disease in the medical community. Thus, the use of the well-known Rotterdam criteria makes it difficult to diagnose PCOS in adolescent girls, since the criteria do not take into account characteristic changes that occur during puberty. Such manifestations as acne, hirsutism, menstrual irregularities, high androgen levels and morphology of polycystic ovaries on pelvic ultrasound imaging should be assessed with due account for age, puberty, hormonal balance with an assessment of the ratio of LH (luteinizing hormone)/FSH (follicle-stimulating hormone) and Free Androgen Index. There is no consensus in the medical community regarding the treatment strategy for PCOS. International communities have identified two main goals in the management of patients: normalization of menstrual function and improvement of the patients’ quality of life by preventing clinical symptoms of hyperandrogenism, and metabolic disorders of hyperplastic processes in target organs.Our analysis of objective scientific data showed that modern monophasic combined oral contraceptives (COCs) supplemented by of a folate component should be used to treat young female patients with PCOS, hyperandrogenism and psychosomatic disorders.

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

Hepatology ◽  
2017 ◽  
Vol 66 (1) ◽  
pp. 46-56 ◽  
Author(s):  
Aijaz Ahmed ◽  
Stevan A. Gonzalez ◽  
George Cholankeril ◽  
Ryan B. Perumpail ◽  
Justin McGinnis ◽  
...  
Keyword(s):  
United States ◽  
Liver Transplant ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Cost Effective ◽  
The United States ◽  
Direct Acting Antivirals ◽  
Cost Effective Treatment ◽  
Direct Acting

scholarly journals LncRNA-MCM3AP-AS1 Promotes the Progression of Infantile Hemangiomas by Increasing miR-138-5p/HIF-1α Axis-Regulated Glycolysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Haijun Mei ◽  
Hua Xian ◽  
Jing Ke
Keyword(s):  
Endothelial Cells ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Benign Tumor ◽  
Aerobic Oxidation ◽  
Infantile Hemangioma ◽  
Promoting Effect ◽  
Multiple Tumors ◽  
Common Benign Tumor ◽  
Non Coding Rnas

Infantile hemangioma (IH) is a common benign tumor of endothelial cells in infants. Most hemangiomas are self-limited, but a few may develop and lead to serious complications that affect the normal life of children. Therefore, finding an effective treatment strategy for IH is a pressing need. Recent studies have demonstrated that non-coding RNAs affect the progression of multiple tumors. This study aims to investigate the mechanism by which LncRNA-MCM3AP-AS1 promotes glycolysis in the pathogenesis of IH. We first documented that the expression of LncRNA MCM3AP-AS1 was significantly upregulated in IH. Furthermore, we demonstrated that MCM3AP-AS1 bound to miR-106b-3p which promotes glycolysis in IH. In addition, we found that inhibition of HIF-1α contributed to the transformation of glycolysis to normal aerobic oxidation, partially reversed the promoting effect on glycolysis by the up-regulation of LncRNA MCM3AP-AS1 in IH disease. More importantly, we demonstrated this phenomenon existed in IH patients. Taken together, we demonstrate that LncRNA-MCM3AP-AS1 promotes the progression of infantile hemangiomas by increasing the glycolysis via regulating miR-138-5p/HIF-1α axis.

scholarly journals MP57-03 COMBINATION OF ANDROGEN RECEPTOR INHIBITOR AND CISPLATIN, AN EFFECTIVE TREATMENT STRATEGY FOR UROTHELIAL CARCINOMA OF THE BLADDER

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Ashish Tyagi ◽  
Balaji Chandrasekaran ◽  
Venkatesh Kolluru ◽  
Samarpit Rai ◽  
Murali Ankem ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Urothelial Carcinoma ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Carcinoma Of The Bladder ◽  
Receptor Inhibitor

Unveiling Role of MicroRNAs as Treatment Strategy and Prognostic Markers in Triple Negative Breast Cancer

2020 ◽  
Vol 21 (15) ◽  
pp. 1569-1575
Author(s):  
Acharya Balkrishna ◽  
Rashmi Mittal ◽  
Vedpriya Arya
Keyword(s):  
Breast Cancer ◽  
Effective Treatment ◽  
Triple Negative Breast Cancer ◽  
Treatment Strategy ◽  
Triple Negative ◽  
Prognostic Markers ◽  
Disease Free Survival ◽  
Free Survival ◽  
Global Regulators

Triple negative breast cancer is the highly aggressive form of breast cancer with high reoccurrence rate and is short of effective treatment strategy. The prognostic markers of it are also not well understood. miRNAs are the global regulators of various cancers on the virtue of its ability to post transcriptional regulation of genes involved in various pathways involved in complicating TNBC. In this review we studied the expression of miRNAs at different stages of TNBC and the role of miRNAs as a tumor suppressor to inhibit cell proliferation, angiogenesis, invasion and metastasis and to induce apoptosis and thereby proposing these miRNAs as an effective treatment strategy against TNBC. miRNA also acts as chemosenstizer in enhancing chemosensitivity of conventional drugs against resistant TNBC cells. The present review emphasizes the importance of miRNAs as prognostic markers to determine the overall survival, disease free survival and distant metastasis free survival rate in TNBC patients. We speculate that miRNA can present themselves as an effective treatment strategy and prognostic marker against TNBC.

Sign in / Sign up

Export Citation Format

Share Document